Genprex ( (GNPX) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Genprex, Inc., a biotechnology company, has filed a Form 12b-25 indicating a delay in submitting its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The delay is primarily due to the need for additional time to complete and finalize the company’s financial statements and related audit procedures. Genprex has assured that the report will be filed within fifteen calendar days following the original due date. The company does not anticipate any significant changes in its financial results compared to the previous fiscal year. Genprex is committed to maintaining compliance with regulatory requirements, as indicated by the notification signed by Ryan Confer, the President, CEO, and CFO.
More about Genprex
YTD Price Performance: -72.78%
Average Trading Volume: 1,960,087
Technical Sentiment Signal: Buy
Current Market Cap: $2.31M
See more insights into GNPX stock on TipRanks’ Stock Analysis page.